UK Markets closed

Pharmagest Interactive SA (0R9T.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
78.99-0.11 (-0.14%)
At close: 05:42PM BST
Full screen
Previous close79.10
Open79.20
Bid0.00 x 0
Ask0.00 x 0
Day's range78.95 - 79.30
52-week range78.95 - 79.30
Volume2,003
Avg. volumeN/A
Market cap1.158B
Beta (5Y monthly)0.91
PE ratio (TTM)34.65
EPS (TTM)2.28
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    EQUASENS (Pharmagest Interactive): Q1 2022 revenue: +9.03% to €49.36m

    Villers-lès-Nancy, 12 May 2022 - 6:00 p.m. (CET) PRESS RELEASE Q1 2022 revenue: +9.03% to €49.36m Name change completed: Pharmagest Group becomes Equasens Group The Extraordinary General Meeting of 6 May 2022 adopted the resolution changing Pharmagest Group’s name to Equasens Group. Group's Q1 2022 revenue up 9.03% to €49.36m (+7% to €48.44m like-for-like).The Group confirms its positive momentum and growth targets for 2022. In €mQ1 2021Q1 2022 *ChangeRevenue45.2749.36+ 9.03 % * unaudited **** O

  • Globe Newswire

    Pharmagest Interactive: RESULTS OF THE VOTE ON THE RESOLUTIONS SUBMITTED TO THE EXTRAORDINARY GENERAL MEETING OF 6 MAY 2022

    Villers-lès-Nancy, 10 May 2022 - 7:00 a.m. (CET) PRESS RELEASE RESULTS OF THE VOTE ON THE RESOLUTIONS SUBMITTED TO THE EXTRAORDINARY GENERAL MEETING OF 6 MAY 2022 Number of shares comprising the share capital: 15,174,125 Number of shares entitled to vote: 15,062,990 Number of shares with voting rights possessed by shareholders present, represented or having voted by mail: 13,085,075 The Extraordinary General Meeting met on Friday 6 May 2022 at 5 p.m. at the Company's registered office and approv

  • Globe Newswire

    Pharmagest Interactive: 2021 Net Profit: +25.97% to €41.15m and new name proposal for the Group

    Villers-lès-Nancy, 25 March 2022 - 7:00 p.m. (CET) PRESS RELEASE High quality, strong and profitable growth2021 Net Profit: +25.97% to €41.15m Revenue: +12.41% to €193.07m All Divisions contributed to this performance.With the integration of PROKOV EDITIONS in Q4 2021, Pharmagest Group confirms the relevance and effectiveness of its expanded offering with a specific range of software solutions for office-based private practitioners. Solid earnings growth: Operating Profit: +8.95% to €50.26mNet P